Sort   by:  
 Page size 
ProteomicsSingle-shot proteome of AML cell lines and AML ex vivo cells upon selinexor treatment
Single-shot proteome analysis of 4 AML cell lines; 2 selinexor sensitive cell lines (GDM-1, MV4-11) and 2 resistant cell lines (NOMO-1 and PL-21) and ex vivo AML cells from 30 patients treated with DMSO (B; before treatment) or 1 uM selinexor (A; after treatment) for 6 hours.
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD033515 | Pride
Human Lc-msms Aml 
ProteomicsPhosphoproteomics analysis of Selinexor response in AML ex vivo patient samples and cell lines
We used mass spectrometry-based proteomics to perform a phosphoproteomics analysis of selinexor-treated ex vivo AML patient samples (n=20) and 4 AML cell lines (PL-21, NOMO-1, GDM-1 and MV4-11). For quantitative phosphoproteomics, we used a tandem mass tag (TMT)-based approach. Conditions for the TM...
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD017660 | Pride
Lc-msms Selinexor Human Aml 
ProteomicsLC-MSMS of the MHC-I immunopeptidome of AML cell lines
The hypomethylating agent 5-azacytidine (AZA) is the first-line induction therapy for AML patients unsuitable for intensive chemotherapy. The anti-tumor effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic region...
ORGANISM(S): Homo sapiens (Human) 
2024-04-17 | PXD038663 | Pride
Acute myeloid leukemia Eres 5-azacitidine Immunopeptidome Mhc-i 
ProteomicsAn Informatic Approach to Chimeric Antigen Receptor Discovery Integrates Proteomics and Transcriptomics to Identify Novel Combinatorial Pairs
Chimeric antigen receptor (CAR) therapy targeting CD19 yielded remarkable outcomes in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute myeloid leukemia (AML), we probed the AML surfaceome for over-expressed molecules with potentially tolerable systemic expressio...
ORGANISM(S): Homo sapiens (Human) 
2017-10-24 | PXD007552 | Pride
Tf Thpi Monomac Kasumi Human aml cell lines lc-msms Molm13 09aml 
ProteomicsEvaluation of differential peptide loading on TMT-based proteomic and phosphoproteomic data quality
Investigating the impacts on MS data quantitation reproducibility when loading differential amounts of peptides, ranging from 20 to 400 ug, across channels of TMT 11 multiplexes. PTRC_Exp9 files represent global proteome and phosphoproteome data generated from PBMCs isolated from AML patients, acqui...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2020-11-05 | MSV000086417 | MassIVE
ProteomicsLC-MSMS of the MHC-I immunopeptidome of AML cell line, THP-1
The hypomethylating agent 5-azacytidine (AZA) is the first-line induction therapy for AML patients unsuitable for intensive chemotherapy. The anti-tumor effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hyperm...
ORGANISM(S): Homo sapiens (Human) 
2024-04-17 | PXD046853 | Pride
Hypomethylating agents (hmas) Acute myeloid leukemia Eres Autophagy inhibition Immunopeptidome Mhc-i 
ProteomicsAssessment of global peptide abundance in TOE1 depleted myeloid leukaemia cells
Acute myeloid leukaemia (AML) is an aggressive haematological malignancy characterised by the clonal proliferation of myeloid progenitor cells in the bone marrow and peripheral blood. Dysregulation of the Wnt/β-catenin pathway has been implicated in the establishment and maintenance of leukaemic ste...
ORGANISM(S): Homo sapiens (Human) 
2026-04-29 | PXD070891 | Pride
Aml  hel  oci-aml2  toe1  hspc  human  shrna  leukaemia 
ProteomicsCharacterisation of the Beta-Catenin cytoplasmic/nuclear interactome in leukaemia cells
Canonical Wnt/B-catenin signaling is frequently dysregulated in myeloid leukemias and is implicated in leukemogenesis. Nuclear-localized β-catenin is indicative of active Wnt signaling and is frequently observed in acute myeloid leukemia (AML) patients; however, some patients exhibit little or no β-...
ORGANISM(S): Homo sapiens (Human) 
2019-01-11 | PXD009305 | Pride
Wnt signalling Myeloid B-catenin Interactome Leukaemia 
ProteomicsInhibition of CBP synergizes with the RNA-dependent mechanisms of azacitidine by limiting protein translation
The nucleotide analogue azacitidine (AZA) interferes with RNA and DNA metabolism and is currently the best treatment option for a subset of patients with high-risk myelodysplastic syndromes. However, only half of treated patients respond and almost all patients that initially respond eventually rela...
ORGANISM(S): Homo sapiens (Human) 
2021-09-22 | PXD021738 | Pride
Hypomethylating agents  azacitidine  epigenetic regulation  lysine acetyl tranferase inhibitors  creb binding protein / cbp / p300  shrna screen  protein synthesis Clonal hematopoietic disorders Myelodysplastic syndromes  secondary acute myeloid leukemia 
Sort   by:  
 Page size